Entero Healthcare Q1FY27: Growth stayed strong, and margins finally hit 5 percent

Entero Healthcare Solutions began FY27 with a sharp improvement in both scale and profitability. Consolidated revenue in Q1FY27 was INR 1,940.5 crore, up 38 percent year on year. The company also highlighted like-for-like growth of 40 percent, adjusting for the impact of revenue recognized on a net margin basis and the divestment of a subsidiary in the base period.

Profitability improved faster than revenue. Gross profit increased to INR 221.4 crore, with gross margin expanding to 11.4 percent versus 9.9 percent a year ago. EBITDA nearly doubled to INR 97.0 crore and EBITDA margin reached 5.0 percent. Profit after tax was INR 52.1 crore, translating to a PAT margin of 2.7 percent.

What drove the quarter

Management broke Q1FY27 growth into two parts. Organic revenue growth was 17.8 percent on a reported basis and 19.6 percent on a like-for-like basis. Inorganic growth was 20.4 percent, and management clarified that this was entirely due to calendarisation of acquisitions completed in the prior year. There were no new acquisitions during the quarter.

One deliberate decision reduced reported growth, but supported profitability. Management said it continued to exit certain low-margin businesses to release working capital for higher-return opportunities, and this impacted reported growth by around 2.5 percent in Q1FY27.

The margin expansion was attributed to three levers: scale-led procurement economies, a growing share of MedTech where Entero plays a larger commercial role, and the deliberate exit from low-margin accounts.

Capital efficiency improved, but cash flow will be watched

Entero reported better working capital efficiency, with net operating working capital days improving to 61 days in Q1FY27 from 66 days in Q1FY26. Return ratios moved sharply higher. ROCE was reported at 21.1 percent versus 11.5 percent a year ago. ROE improved to 20.4 percent versus 9.0 percent.

Two disclosures from the call are relevant for investors tracking cash and earnings quality.

First, finance costs rose meaningfully. Finance costs were INR 18.1 crore in Q1FY27 versus INR 8.3 crore in Q1FY26. The CFO attributed the increase largely to the full-quarter interest impact of acquisition-related debt and said interest costs should remain broadly in the same range through the rest of FY27.

Second, the minority interest line item remains material. Non-controlling interest was INR 13.9 crore in the quarter. Management explained that some acquisitions were structured as majority buyouts rather than 100 percent acquisitions, and the company has contractually defined call options to acquire residual minority stakes over a defined time horizon. Management indicated these time horizons are typically 2 to 5 years, and that valuation multiples are consistent with the multiples paid at the time of original acquisition.

MedTech is positioned as the medium-term margin lever

The investor presentation states Entero’s FY27 MedTech revenue is expected to cross INR 1,000 crore. On the earnings call, management reiterated that MedTech revenue is on track to cross INR 1,000 crore in FY27 on an organic basis and that MedTech carries higher gross and EBITDA margins than the core pharmaceutical distribution business.

The strategic rationale in the presentation also frames MedTech as a large and fast-growing market, synergistic with distribution, and offering a higher margin profile for distributors. The company said current business and acquisitions are focused around in vitro diagnostics and cardiology or orthopedic devices, which are described as large and high-growth segments.

Management also clarified that profitability is not purely tied to the product category, but to the role Entero plays in the transaction. In areas where Entero plays a demand generation role rather than only demand fulfilment, the company sees higher gross margin potential. Management said this dynamic is more common in MedTech than in core pharma distribution.

Operating scale continued to expand

The company continued to disclose operating scale metrics that support the distribution platform narrative. In Q1FY27 it served 72,000 plus retail customers and 2,300 plus hospital customers. It billed 83,400 plus SKUs and had 3,000 plus relationships with healthcare product manufacturers. The platform was supported by 138 warehouses across 475 districts in 19 states.

Management linked outperformance versus the Indian Pharmaceutical Market to increasing wallet share and customer growth, driven by better product availability, fill rates, a wider range and a technology-enabled buying experience.

Guidance stayed unchanged, with integration the near-term focus

Management reiterated FY27 guidance of consolidated revenue growth of approximately 23 percent year on year, excluding any contribution from new acquisitions. It also reiterated EBITDA margin guidance of 5 percent and an EBITDA to operating cash flow conversion of 50 percent, with management emphasizing that operating cash flow should be viewed on an annual basis due to seasonality.

The clearest strategic message from Q1FY27 was the decision to pause major acquisitions and focus on consolidating and integrating the platform built over the prior two years. Management said it remains open to compelling opportunities, especially in the last quarter of the year, but the stated priority is organic scaling and integration.

The quarter therefore sets up a simple investor checklist for the rest of FY27: sustain the 5 percent EBITDA margin base, keep working capital in check, execute on the INR 1,000 crore plus MedTech ambition, and demonstrate that growth can continue even with a muted acquisition pipeline.